Free Trial

BioLineRx Q3 2024 Earnings Report

BioLineRx logo
$2.65 -0.29 (-9.86%)
As of 04:00 PM Eastern

BioLineRx EPS Results

Actual EPS
-$2.80
Consensus EPS
-$3.20
Beat/Miss
Beat by +$0.40
One Year Ago EPS
N/A

BioLineRx Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

BioLineRx Announcement Details

Quarter
Q3 2024
Time
Before Market Opens

Conference Call Resources

Remove Ads

BioLineRx Earnings Headlines

BioLineRx (NASDAQ:BLRX) Earns "Hold" Rating from Jones Trading
Q1 Earnings Forecast for BioLineRx Issued By HC Wainwright
Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
BioLineRx stock rating cut to Hold at Jones Trading
BLRX: 2024 Financial Results
BioLineRx downgraded to Hold from Buy at JonesResearch
See More BioLineRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioLineRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioLineRx and other key companies, straight to your email.

About BioLineRx

BioLineRx (NASDAQ:BLRX), a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

View BioLineRx Profile

More Earnings Resources from MarketBeat